

## **RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans**

### **SUPPLEMENTARY MATERIALS**

**Supplementary Dataset 1: RNA sequencing analysis of TAS of Black American (BA) and White American (WA) prostate cancer (PCa) patients.** See Supplementary Dataset 1

**Supplementary Table 1A: 3550 differentially transcribed genes in 7 BA prostate TAS cases versus 7 WA prostate TAS cases; corrected  $p < 0.05$ ; FC  $\geq 2.5$  in both directions.**

**Supplementary Table 1B: Canonical pathways of 1706 significantly differentially downregulated transcribed genes in 7 BA prostate TAS cases versus 7 WA prostate TAS cases; corrected  $p < 0.05$ .**

**Supplementary Table 1C: Canonical pathways of 1844 significantly differentially upregulated transcribed genes in 7 BA prostate TAS cases versus 7 WA prostate TAS cases; corrected  $p < 0.05$ .**

**Supplementary Dataset 2: Analysis of published RNA sequencing data of prostate cancer tissue samples from BA and WA patients.** See Supplementary Dataset 2

**Supplementary Table 2A: 1408 differentially transcribed genes in 15 BA prostate tumor cases versus 30 WA prostate tumor cases; corrected  $p < 0.05$ ; FC  $\geq 1.5$  in either direction.**

**Supplementary Table 2B: Canonical pathways of 932 significantly differentially upregulated transcribed genes in 15 BA prostate tumor cases versus 30 WA prostate tumor cases; corrected  $p < 0.05$ .**

**Supplementary Table 2C: Canonical pathways of 476 significantly differentially downregulated transcribed genes in 15 BA prostate tumor cases versus 30 WA prostate tumor cases; corrected  $p < 0.05$ .**

**Supplementary Table 2D: Diseases and functions associated with 932 significantly differentially upregulated transcribed genes in 15 BA prostate tumor cases versus 30 WA prostate tumor cases; corrected  $p < 0.05$ .**

**Supplementary Table 2E: Diseases and functions associated with 476 significantly differentially downregulated transcribed genes in 15 BA prostate tumor cases versus 30 WA prostate tumor cases; corrected  $p < 0.05$ .**

**Supplementary Table 2F: Gene network analysis of 476 significantly differentially downregulated transcribed genes in 15 BA prostate tumor cases versus 30 WA prostate tumor cases; corrected  $p < 0.05$ .**

**Supplementary Table 2G: Gene network analysis of 932 significantly differentially upregulated transcribed genes in 15 BA prostate tumor cases versus 30 WA prostate tumor cases; corrected  $p < 0.05$ .**

**Supplementary Dataset 3: Transcriptome analysis of BA versus WA PCa patients in tumor and TAS. See Supplementary Dataset 3**

**Supplementary Table 3A: 2500 differentially transcribed genes with the highest significance in 7 BA prostate TAS cases versus 7 WA prostate TAS cases; corrected  $p < 0.05$ .**


**Supplementary Table 3B: 2500 differentially transcribed genes with the highest significance in 15 BA prostate tumor cases versus 30 WA prostate tumor cases; corrected  $p < 0.05$ .**

**Supplementary Table 3C: Comparative pathway analysis on top differentially transcribed genes downregulated in BA versus WA patients between prostate TAS and tumors; corrected  $p < 0.05$ .**


**Supplementary Table 3D: Comparative pathway analysis on top differentially transcribed genes upregulated in BA versus WA patients between prostate TAS and tumors; corrected  $p < 0.05$ .**

**Supplementary Table 3E: Gene network analysis of 149 discordant genes in prostate TAS and tumors of BA versus WA patients; corrected  $p < 0.05$ .**


**Supplementary Table 3F: Gene network analysis of 94 concordant genes in prostate TAS and tumors of BA versus WA patients; corrected  $p < 0.05$ .**




Supplementary Figure 1: Venn diagrams of the different ancestry compositions identified using LASER in 99 FFPE samples from BA and WA PCa patients (GSE54460).




Supplementary Figure 2: Natural killer cell signaling genes significantly downregulated in the TAS of BA ( $n = 7$ ) compared to WA ( $n = 7$ ) prostate cancer samples. Y axis represents normalized  $\log_2$  signal values (normalized reads) ( $p_{\text{adj}} < 0.05$ ). Each dot represents a patient.



**Supplementary Figure 3: Comparison of published regulation status of genes in BA vs WA PCa samples and our gene list.** A study by Hardiman et al. from 10 self-reported BA and 17 self-reported WA PCa patients identified 242 upregulated genes [21]. We identified 65 overlapping genes with our list of 1408 genes, at 98% concordance. The heat map shows the expression levels of those 65 overlapping concordant genes in 15 BA compared to 30 WA prostate cancer patients. Red depicts up- and blue depicts downregulation. N is the number of genes.



**Supplementary Figure 4: Gene network analysis of statistically significant (corrected  $p$  value < 0.05) up- and downregulated genes in BA ( $n = 15$ ) versus WA ( $n = 30$ ) PCa samples.** The networks shown are among those with the highest significance of connections between molecules in the network as indicated by their score. Blue nodes indicate downregulated gene expression and red nodes indicate upregulated gene expression. Darker shades of the nodes indicate higher regulation ratios. Dotted lines represent indirect interactions while solid lines represent direct interactions. White colored notes are in the pathway, but not in our dataset.



Supplementary Figure 5: Overlapping genes in tumor and TAS of BA versus WA PCa patients with concordant and discordant regulations.

**Supplementary Table 1: Transcriptome analysis and clinical characteristics of TAS of self-reported BA ( $n = 9$ ) and WA ( $n = 11$ ) PCa patients**

| PCa-TAS       | Reported Race | Location | Relapse Definition | Follow-up (months) | Gleason Score | Total Gleason Score | Given Age | Race Ratio | Race Breakdown                | Number of Reads | Aligned Reads |
|---------------|---------------|----------|--------------------|--------------------|---------------|---------------------|-----------|------------|-------------------------------|-----------------|---------------|
| <i>TAS1*</i>  | Black         | MUSC     | R                  | 24                 | 3+5           | 8                   | 60        | 7:2:1      | Africa: C/S Asia: Middle East | 58,353,208      | 9,146,862     |
| <i>TAS2*</i>  | Black         | MUSC     | N                  | 59                 | 3+4           | 7                   | 61        | 10:0       | Africa                        | 17,275,140      | 9,540,061     |
| <i>TAS3*</i>  | Black         | MUSC     | R                  | 1                  | 3+4           | 7                   | 66        | 10:0       | Africa                        | 100,431,162     | 28,995,535    |
| <i>TAS4*</i>  | Black         | MUSC     | R                  | 73                 | 3+3           | 6                   | 60        | 6:2:2      | Africa: C/S Asia: Middle East | 14,218,314      | 8,651,441     |
| <i>TAS5*</i>  | Black         | UCI      | R                  | 11                 | 4+5           | 9                   | 57        | 10:0       | Africa                        | 46,529,804      | 22,448,895    |
| <i>TAS6*</i>  | Black         | MUSC     | R                  | 23                 | 4+5           | 9                   | 64        | 7:2:1      | Africa: C/S Asia: Middle East | 13,857,852      | 5,685,592     |
| <i>TAS7*</i>  | Black         | MUSC     | N                  | 36                 | 3+4           | 7                   | 62        | 5:3:2      | Africa: C/S Asia: Middle East | 9,567,576       | 3,693,855     |
| <i>TAS8</i>   | Black         | MUSC     | R                  | 89                 | 3+4           | 7                   | 56        | 6:4        | Middle East: C/S Asia         | 34,398,988      | 4,202,710     |
| <i>TAS9</i>   | Black         | UCI      | N                  | 13                 | 3+4           | 7                   | 66        | 6:4        | Middle East: C/S Asia         | 175,188,492     | 65,452,830    |
| <i>TAS10*</i> | White         | UCI      | R                  | 95                 | 4+4           | 8                   | 62        | 10:0       | Middle East                   | 8,702,216       | 5,104,814     |
| <i>TAS11*</i> | White         | UCI      | N                  | 82                 | 3+4           | 7                   | 66        | 10:0       | Middle East                   | 60,372,832      | 35,386,525    |
| <i>TAS12*</i> | White         | UCI      | R                  | 24                 | 3+4           | 7                   | 53        | 8:1:1      | Europe: Middle East: C/S Asia | 19,391,098      | 11,692,864    |
| <i>TAS13*</i> | White         | UCI      | R                  | 19                 | 4+4           | 8                   | 43        | 10:0       | Europe                        | 3,800,718       | 1,053,081     |
| <i>TAS14*</i> | White         | UCI      | R                  | 16                 | 4+5           | 9                   | 63        | 10:0       | Europe                        | 18,000,216      | 6,707,433     |
| <i>TAS15*</i> | White         | UCI      | R                  | 17                 | 4+4           | 8                   | 68        | 8:2        | Europe: Middle East           | 49,658,208      | 17,847,446    |
| <i>TAS16*</i> | White         | UCI      | R                  | 22                 | 4+3           | 7                   | 66        | 10:0       | Europe                        | 5,539,412       | 1,309,553     |
| <i>TAS17</i>  | White         | UCI      | N                  | 61                 | 3+3           | 6                   | 60        | 10:0       | C/S Asia                      | 31,396,544      | 17,660,670    |
| <i>TAS18</i>  | White         | UCI      | R                  | 90                 | 3+4           | 7                   | 63        | 9:1        | C/S Asia: Europe              | 26,390,916      | 8,587,454     |
| <i>TAS19</i>  | White         | UCI      | R                  | 2                  | 4+5           | 9                   | 59        | 7:3        | C/S Asia: America             | 14,017,038      | 3,781,150     |
| <i>TAS20</i>  | White         | UCI      | R                  | 15                 | 4+5           | 9                   | 67        | 9:1        | C/S Asia: Europe              | 5,513,162       | 1,008,259     |

Abbreviations: TAS: Tumor adjacent stroma; PCa: Prostate cancer; UCI: University of California, Irvine; MUSC: Medical University of South Carolina; C/S: Central/South; R: Relapse; N: Non-relapse. (\*) denotes patients selected for gene expression analysis.

**Supplementary Table 2: Clinical characteristics and geographical ancestry of GSE54460 PCa patients**

| PCa-Tumor    | Reported Race | Location | Given Age | BCR (months) | Gleason Score | Total Gleason Score | Follow-up (months) | Race Ratio | Race Breakdown                |
|--------------|---------------|----------|-----------|--------------|---------------|---------------------|--------------------|------------|-------------------------------|
| <i>BA1*</i>  | Black         | VA       | 63        | NA           | 5+3           | 8                   | 59.5               | 10:0       | Africa                        |
| <i>BA2*</i>  | Black         | VA       | 62        | NA           | 3+4           | 7                   | 61.5               | 10:0       | Africa                        |
| <i>BA3*</i>  | Black         | VA       | 69        | NA           | 3+4           | 7                   | 67.9               | 10:0       | Africa                        |
| <i>BA4*</i>  | Black         | VA       | 70        | NA           | 3+4           | 7                   | 106.6              | 10:0       | Africa                        |
| <i>BA5*</i>  | Black         | VA       | 47        | NA           | 3+4           | 7                   | 69.8               | 10:0       | Africa                        |
| <i>BA6*</i>  | Black         | VA       | 56        | NA           | 3+3           | 6                   | 51.5               | 10:0       | Africa                        |
| <i>BA7*</i>  | Black         | VA       | 62        | NA           | 3+4           | 7                   | 71.9               | 10:0       | Africa                        |
| <i>BA8*</i>  | Black         | VA       | 54        | NA           | 3+4           | 7                   | 73.8               | 10:0       | Africa                        |
| <i>BA9*</i>  | Black         | VA       | 50        | NA           | 3+4           | 7                   | 77.3               | 10:0       | Africa                        |
| <i>BA10*</i> | Black         | VA       | 53        | 1.6          | 3+4           | 7                   | 1.6                | 10:0       | Africa                        |
| <i>BA11*</i> | Black         | VA       | 66        | 26.6         | 4+3           | 7                   | 26.6               | 10:0       | Africa                        |
| <i>BA12*</i> | Black         | VA       | 55        | 0.7          | 4+5           | 9                   | 0.7                | 10:0       | Africa                        |
| <i>BA13*</i> | Black         | VA       | 58        | 60.5         | 3+4           | 7                   | 60.5               | 10:0       | Africa                        |
| <i>BA14*</i> | Black         | VA       | 52        | 26           | 3+4           | 7                   | 26                 | 10:0       | Africa                        |
| <i>BA15*</i> | Black         | VA       | 62        | 2.2          | 4+4           | 8                   | 2.2                | 9:1        | Africa: C/S Asia              |
| <i>BA16</i>  | Black         | VA       | 69        | NA           | 3+4           | 7                   | 69.5               | 8:2        | Africa: C/S Asia              |
| <i>BA17</i>  | Black         | VA       | 56        | NA           | 3+4           | 7                   | 68                 | 8:2        | Africa: C/S Asia              |
| <i>BA18</i>  | Black         | VA       | 56        | NA           | 3+4           | 7                   | 118.3              | 9:1        | Africa: C/S Asia              |
| <i>BA19</i>  | Black         | VA       | 50        | NA           | 3+4           | 7                   | 96.6               | 10:0       | Africa                        |
| <i>BA20</i>  | Black         | VA       | 57        | NA           | 4+3           | 7                   | 89.3               | 7:2:1      | Africa: C/S Asia: Middle East |
| <i>BA21</i>  | Black         | VA       | 60        | 26.6         | 4+3           | 7                   | 26.6               | 7:2:1      | Africa: C/S Asia: Middle East |
| <i>BA22</i>  | Black         | VA       | 58        | 101.1        | 3+4           | 7                   | 101.1              | 8:2        | Africa: C/S Asia              |
| <i>BA23</i>  | NA            | MCC      | 43        | NA           | 3+4           | 7                   | 50                 | 10:0       | Africa                        |
| <i>BA24</i>  | NA            | UTP      | 55        | 0            | 3+4           | 7                   | 50                 | 10:0       | Africa                        |
| <i>BA25</i>  | NA            | UTP      | 71        | 0            | 3+4           | 7                   | 54                 | 10:0       | Africa                        |
| <i>BA26</i>  | NA            | UTP      | 51        | 0            | 4+3           | 7                   | 100                | 10:0       | Africa                        |
| <i>BA27</i>  | NA            | VA       | 59        | 36           | 4+4           | 8                   | 36                 | 10:0       | Africa                        |
| <i>WA1*</i>  | White         | VA       | 62        | NA           | 4+3           | 7                   | 62.4               | 10:0       | Europe                        |
| <i>WA2*</i>  | White         | VA       | 52        | NA           | 3+4           | 7                   | 50.4               | 10:0       | Europe                        |
| <i>WA3*</i>  | White         | VA       | 51        | NA           | 3+3           | 6                   | 64.2               | 10:0       | Europe                        |
| <i>WA4*</i>  | White         | VA       | 64        | NA           | 4+4           | 8                   | 171.1              | 10:0       | Europe                        |
| <i>WA5*</i>  | White         | VA       | 69        | NA           | 3+4           | 7                   | 48.6               | 10:0       | Europe                        |
| <i>WA6*</i>  | White         | VA       | 70        | NA           | 3+4           | 7                   | 116.5              | 10:0       | Europe                        |
| <i>WA7*</i>  | White         | VA       | 65        | NA           | 3+4           | 7                   | 148.2              | 10:0       | Europe                        |
| <i>WA8*</i>  | White         | VA       | 67        | NA           | 3+4           | 7                   | 116.9              | 10:0       | Europe                        |
| <i>WA9*</i>  | White         | VA       | 64        | NA           | 3+4           | 7                   | 155.1              | 10:0       | Europe                        |
| <i>WA10*</i> | White         | VA       | 61        | NA           | 4+3           | 7                   | 31.8               | 10:0       | Europe                        |
| <i>WA11*</i> | White         | VA       | 50        | NA           | 3+4           | 7                   | 100.2              | 8:1:1      | Europe: Middle East: C/S Asia |
| <i>WA12*</i> | White         | VA       | 54        | NA           | 3+4           | 7                   | 95.9               | 10:0       | Europe                        |
| <i>WA13*</i> | White         | VA       | 61        | NA           | 3+4           | 7                   | 83                 | 9:1        | Middle East: C/S Asia         |
| <i>WA14*</i> | White         | VA       | 54        | NA           | 3+4           | 7                   | 64.3               | 10:0       | Europe                        |
| <i>WA15*</i> | White         | VA       | 55        | NA           | 3+4           | 7                   | 82.3               | 10:0       | Middle East                   |
| <i>WA16*</i> | White         | VA       | 66        | NA           | 4+3           | 7                   | 55.6               | 10:0       | Middle East                   |



|                   |       |     |    |        |     |   |        |      |                     |
|-------------------|-------|-----|----|--------|-----|---|--------|------|---------------------|
| WA17 <sup>7</sup> | White | VA  | 62 | NA     | 3+4 | 7 | 34.7   | 10:0 | Europe              |
| WA18 <sup>6</sup> | White | VA  | 65 | NA     | 3+3 | 6 | 63.4   | 10:0 | Middle East         |
| WA19 <sup>9</sup> | White | VA  | 58 | 3.6    | 4+3 | 7 | 3.6    | 10:0 | Europe              |
| WA20 <sup>6</sup> | White | VA  | 64 | 0.8    | 4+4 | 8 | 0.8    | 10:0 | Europe              |
| WA21 <sup>7</sup> | White | VA  | 67 | 3.6    | 3+4 | 7 | 3.6    | 10:0 | Europe              |
| WA22 <sup>6</sup> | White | VA  | 52 | 1      | 4+4 | 8 | 1      | 10:0 | Europe              |
| WA23 <sup>3</sup> | White | VA  | 67 | 95     | 3+4 | 7 | 95     | 10:0 | Europe              |
| WA24 <sup>6</sup> | White | VA  | 67 | 18.3   | 4+3 | 7 | 18.3   | 10:0 | Europe              |
| WA25 <sup>5</sup> | White | VA  | 65 | 1.6    | 4+4 | 8 | 1.6    | 10:0 | Europe              |
| WA26 <sup>6</sup> | White | VA  | 62 | 3.5    | 3+4 | 7 | 3.5    | 10:0 | Europe              |
| WA27 <sup>7</sup> | White | VA  | 67 | 11.8   | 3+4 | 7 | 11.8   | 9:1  | Middle East: Europe |
| WA28 <sup>6</sup> | White | VA  | 62 | 48.9   | 4+3 | 7 | 48.9   | 10:0 | Middle East         |
| WA29 <sup>9</sup> | White | VA  | 59 | 2.8    | 4+3 | 7 | 2.8    | 9:1  | Europe: Middle East |
| WA30 <sup>6</sup> | White | VA  | 57 | 39.9   | 3+4 | 7 | 39.9   | 10:0 | Europe              |
| WA31              | White | VA  | 68 | NA     | 3+4 | 7 | 63.6   | 7:3  | Europe: Middle East |
| WA32              | White | VA  | 65 | NA     | 3+4 | 7 | 160.3  | 8:2  | Europe: Middle East |
| WA33              | White | VA  | 72 | NA     | 3+4 | 7 | 97.9   | 8:2  | Europe: Middle East |
| WA34              | White | VA  | 65 | NA     | 3+4 | 7 | 76.8   | 8:2  | Middle East: Europe |
| WA35              | White | MCC | 78 | NA     | 3+4 | 7 | 119    | 10:0 | Europe              |
| WA36              | White | MCC | 61 | NA     | 3+3 | 6 | 114    | 10:0 | Europe              |
| WA37              | White | MCC | 63 | NA     | 3+3 | 6 | 87     | 7:3  | Middle East: Europe |
| WA38              | White | MCC | 57 | NA     | 3+4 | 7 | 69     | 10:0 | Europe              |
| WA39              | White | MCC | 54 | NA     | 3+4 | 7 | 57     | 10:0 | Europe              |
| WA40              | White | MCC | 66 | 26.5   | 3+3 | 6 | 104.05 | 10:0 | Europe              |
| WA41              | White | MCC | 61 | 22.13  | 3+3 | 6 | 74.24  | 10:0 | Middle East         |
| WA42              | White | MCC | 60 | 154.22 | 3+2 | 5 | 180.56 | 10:0 | Europe              |
| WA43              | White | UTP | 58 | 18     | 3+4 | 7 | 43     | 10:0 | Europe              |
| WA44              | White | UTP | 72 | 0      | 4+4 | 8 | 112    | 10:0 | Europe              |
| WA45              | NA    | MCC | 58 | NA     | 3+4 | 7 | 98     | 10:0 | Europe              |
| WA46              | NA    | UTP | 57 | NA     | 4+3 | 7 | 72     | 10:0 | Europe              |
| WA47              | NA    | UTP | 66 | NA     | 4+4 | 8 | 85     | 10:0 | Europe              |
| WA48              | NA    | UTP | 50 | NA     | 3+3 | 6 | 63     | 10:0 | Europe              |
| WA49              | NA    | UTP | 69 | NA     | 3+4 | 7 | 82     | 10:0 | Europe              |
| WA50              | NA    | UTP | 71 | 38.2   | 5+4 | 9 | 38     | 10:0 | Europe              |
| WA51              | NA    | UTP | 50 | 23     | 3+4 | 7 | 68     | 10:0 | Europe              |
| WA52              | NA    | UTP | 68 | 27.6   | 4+3 | 7 | 82     | 10:0 | Middle East         |
| WA53              | NA    | UTP | 55 | 0      | 3+4 | 7 | 49     | 8:2  | Europe: Middle East |
| WA54              | NA    | UTP | 65 | 8      | 3+4 | 7 | 128    | 10:0 | Europe              |
| WA55              | NA    | UTP | 62 | 21.4   | 3+3 | 6 | 116    | 10:0 | Europe              |
| WA56              | NA    | UTP | 58 | 0      | 3+4 | 7 | 102    | 10:0 | Europe              |
| WA57              | NA    | UTP | 67 | 0      | 4+5 | 9 | 26     | 5:5  | Europe: Middle East |
| WA58              | NA    | UTP | 70 | 0      | 4+4 | 8 | 35     | 10:0 | Europe              |
| WA59              | NA    | UTP | 59 | 0      | 4+3 | 7 | 88     | 10:0 | Europe              |
| WA60              | NA    | UTP | 53 | 43.4   | 5+4 | 9 | 75     | 10:0 | Middle East         |
| WA61              | NA    | UTP | 60 | 29.8   | 3+4 | 7 | 43     | 10:0 | Europe              |
| WA62              | NA    | UTP | 60 | 48.5   | 3+4 | 7 | 49     | 7:3  | Europe: Middle East |

|             |       |     |    |      |     |   |      |      |                       |
|-------------|-------|-----|----|------|-----|---|------|------|-----------------------|
| <i>WA63</i> | NA    | UTP | 65 | 27.6 | 4+3 | 7 | 101  | 10:0 | Europe                |
| <i>WA64</i> | NA    | UTP | 74 | 18.2 | 3+4 | 7 | 79   | 10:0 | Europe                |
| <i>WA65</i> | NA    | UTP | 66 | 49.5 | 3+4 | 7 | 125  | 10:0 | Europe                |
| <i>WA66</i> | NA    | UTP | 57 | 27.5 | 3+4 | 7 | 112  | 9:1  | Europe: Middle East   |
| <i>WA67</i> | NA    | UTP | 66 | 0    | 4+3 | 7 | 72   | 10:0 | Europe                |
| <i>WA68</i> | NA    | UTP | 72 | 9.6  | 4+3 | 7 | 36   | 5:5  | Europe: Middle East   |
| <i>AS1</i>  | White | VA  | 64 | NA   | 3+3 | 6 | 97.3 | 10:0 | C/S Asia              |
| <i>AS2</i>  | White | VA  | 64 | NA   | 4+3 | 7 | 96.1 | 8:2  | C/S Asia: Middle East |
| <i>AS3</i>  | NA    | UTP | 64 | 21.6 | 4+3 | 7 | 89   | 10:0 | C/S Asia              |
| <i>AS4</i>  | NA    | UTP | 58 | 29.9 | 4+3 | 7 | 61   | 10:0 | C/S Asia              |

Abbreviations: BA: Black American; WA: White American; AS: Asian; VA: Atlanta Veterans Administration Medical Center; MCC: Moffitt Cancer Center; UTP: University of Toronto Sunnybrook Health Sciences Center; C/S: Central/South; BCR: biochemical relapse; NA: Not applicable. (\*) denotes patients selected for gene expression analysis.

### Supplementary Table 3: Summary of clinically matched BA ( $n = 15$ ) and WA ( $n = 30$ ) FFPE PCa tumor-enriched samples (GSE54460)

|           | <i>n</i> | No BCR:<br>BCR | Average<br>Age | Gleason<br>Score 6 | Gleason<br>Score 7 | Gleason<br>Score 8 | Gleason<br>Score 9 | Average<br>Follow-Up<br>(Months) | 80-90%<br>Ancestry | 100%<br>Ancestry |
|-----------|----------|----------------|----------------|--------------------|--------------------|--------------------|--------------------|----------------------------------|--------------------|------------------|
| <i>BA</i> | 15       | 9:6            | 59             | 1                  | 11                 | 2                  | 1                  | 50                               | 1                  | 14               |
| <i>WA</i> | 30       | 18:12          | 61             | 2                  | 24                 | 4                  | 0                  | 59                               | 4                  | 26               |

Abbreviations: BA: Black American; WA: White American; BCR: biochemical relapse.